News | January 02, 2007

Study Shoots Down B12 Benefits

A review by physicians at Tulane University School of Public Health and Tropical Medicine shows that Vitamin B12 supplements are not effective in preventing strokes, heart attacks or death in people with a history of vascular disease. A New York Times article reports that Vitamin B12 reduces the blood levels of homocysteine, a risk factor for cardiovascular disease, but the reduction apparently has no effect on survival.

Doctors reviewed 12 studies comprising 16,598 patients who had pre-existing illness. All of the studies showed a reduction in homocysteine levels in people who took folate supplements, but there was no correlation between the amount of reduction in blood levels of homocysteine and the risk of heart attacks, coronary heart disease, stroke or mortality from any cause, and no difference between those who took folate supplements and the participants in control groups who took none.

“We haven’t found any magical supplement pills to prevent cardiovascular disease,” said Dr. Lydia A. Bazzano in the Times article — she is the lead author of the review and an assistant professor of epidemiology at Tulane.

“The things people have to do are hard; they have to quit smoking, exercise, lose weight, eat properly,” Dr. Bazzano continued. “This means getting omega-3 fatty acids and a well-balanced diet in terms of carbohydrates and proteins. And eating fruits and vegetables is always good. No one has been able to contradict that yet.”

Published in the Dec. 13 issue of the Journal of the American Medical Association, the study covered only people who were already ill with vascular disease, but the authors wrote that no randomized, controlled trials have shown a beneficial effect of B12 supplements in preventing vascular disease in healthy people, either.

Related Content

Quantum Genomics Enrolls First Patient in QUORUM Phase IIb Study of Firibastat
News | Pharmaceuticals | June 14, 2019
Quantum Genomics announced the enrollment of the first patient in its QUORUM Phase IIb study of its lead clinical...
FDA Grants Priority Review for Vascepa sNDA
News | Pharmaceuticals | May 29, 2019
Amarin Corp. plc announced that its supplemental new drug application (sNDA) for Vascepa (icosapent ethyl) capsules has...
Vascepa Markedly Reduces First, Repeat and Total Cardiovascular Events
News | Pharmaceuticals | March 29, 2019
Taking a high dose of icosapent ethyl significantly reduces the occurrence of first, subsequent and total ischemic...
Bempedoic Acid Combination Tablet Significantly Lowers LDL-Cholesterol

Image courtesy of Esperion

News | Pharmaceuticals | March 25, 2019
Phase 3 results from Study 2, also known as CLEAR WISDOM, of bempedoic acid were recently presented at the American...
Aurobindo Pharma Adds to Nationwide Valsartan Blood Pressure Medication Recall
News | Pharmaceuticals | January 10, 2019
January 10, 2019 — Aurobindo Pharma USA Inc.
Mylan Expands Nationwide Recall of Valsartan Blood Pressure Medication
News | Pharmaceuticals | December 11, 2018
December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all
Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Overlay Init